Shots:

• Lysogene to get $26M (€22M) upfront cash with equity investment of $2.5M (€2.2M) at a 30% premium- receive development- regulatory- and commercial milestone payments ~$125 M (€108M) with royalties on sales of product
• Sarepta will get hold of exclusive commercial rights to LYS-SAF302 in the US and and has an option to license CNS Gene therapy candidates for $19M(€16M) & Lysogene will have marketing rights in EU
• LYS-SAF302 is an AAV-mediated gene therapy candidate to replace SGSH gene with a healthy gene. In Q4’18 Lysogene will onset the completion of trial while Sarepta will be undertake global manufacturing rights of LYS-SAF302 and supply Lysogene for its territory

Ref: Sarepta Therapeutics | Image: The Business Journals